Drug intelligence / Profile preview

Di'ao Zihuangjing Tablets

Development stage: Unknown
Lead developer: Chengdu Di’ao Pharmaceutical Group
Administration: Oral

Overview

Di'ao Zihuangjing Tablets is a Traditional Chinese Medicine (TCM) formulation developed by Chengdu Di'ao Pharmaceutical Group. It is primarily used to alleviate cancer-related fatigue (CRF) in patients with advanced solid tumors, particularly those undergoing chemotherapy. The formulation is based on TCM principles of tonifying Qi and nourishing Yin, aimed at improving the quality of life and reducing fatigue symptoms. Clinical evaluation has been conducted through multicenter prospective trials, such as ChiCTR2000033710, led by institutions like West China Hospital of Sichuan University, to assess its efficacy in oncology supportive care.

Brand names: Di'ao Zihuangjing Tablets
Other names: Zihuangjing TabletsDi'ao Zihuangjing Pian

Beyond the preview

Go deeper on Di'ao Zihuangjing Tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Di'ao Zihuangjing Tablets.

Explore the full profile